



# GMP Manufacturing Facility Build-out Progress Slideshow



Nasdaq: APDN


17 December 2024









# Safe Harbor Statement


The statements made by Applied DNA in this presentation may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. These forward-looking statements are based largely on the Company’s expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including statements regarding its belief that restructuring will position the company for future growth potential, its goal to position the company for long term-growth and value creation and the potential to achieve that goal, the future success of its Linea™ DNA and Linea™ IVT platforms and future reductions in operating expenses. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from our Linea IVT and or Linea DNA platforms, the fact that there has never been a commercial drug product utilizing PCR-produced DNA technology and/or the Linea IVT platform approved for therapeutic use, the unknown amount of revenues and profits that will result from its TR8™ PGx testing service, the unknown outcome of the potential divestiture of the Company’s CertainT® Platform, and if successfully divested, the unknown consideration that will be received by the Company, the limited market acceptance for its CertainT Platform, as well as various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including its Annual Report on Form 10-K filed on December 7, 2023, its Quarterly Reports on Form 10-Q filed on February 8, 2024, May 10, 2024, August 8, 2024, and other reports it files with the SEC, which are available at [www.sec.gov](http://www.sec.gov). Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.








Quality  
Control  
Laboratory



Quality Control Laboratory



## Incoming Quality Assurance






Back to GMP floor plan



## Warehouse






Back to GMP floor plan



## Dispensary





Back to GMP floor plan



More>>



Workstations/equipment to be moved in coordination with production of current-quarter, non-GMP orders.

## Production 1




Back to GMP floor plan




Workstations/equipment to be moved in coordination with production of current-quarter, non-GMP orders.

## Production 1






Back to GMP floor plan



## Supplies and Materials



Back to GMP floor plan



Workstations/equipment to be moved in coordination with production of current-quarter, non-GMP orders.


## Production 2




Back to GMP floor plan



## Gowning






## Pre-Gowning and Prep



Back to QCL floor plan



## Quality Control Laboratory





# Thank you!



applieddnasciences

Investor Relations:  
[sanjay.hurry@adnas.com](mailto:sanjay.hurry@adnas.com)